Vinpocetine for cognitive impairment and dementia

Szatmári, Szabolcs; Whitehouse, Peter J.

doi:10.1002/14651858.cd003119

Cited by 107 publications

(102 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The brain pathway for ascending (fusion) CFF is highly differ from descending (flickering) CFF pathway, the flickering neurotransmitter is mainly noradrenalin while the neurotransmitter for fusion is mainly dopamine and serotonin [18] , this explain the significant effect of vinpocetine on flickering CFF and insignificant effect on the ascending CFF in our study.…”

Section: Discussionmentioning

confidence: 50%

The Effects of Vinpocetine on the Psychomotor Performances: Randomized clinical trial, single blind random clinical study

Al-Kuraishy¹,

Al-Windy²,

Al-Gareeb³

2012

JNUS

View full text Add to dashboard Cite

Psychomotor performance parameters reflects the psychomotor and cognitive function in human being, these parameters includes TRT (total reaction time), RRT (recognition reaction time) and MRT (movement reaction time), also critical flickering fusion frequency (CFFF) which either ascending CFF or descending CFF.Vinpocetine drug is introduced in this study as single oral dose of 5mg and ten males medically students enrolled in this study, each subject do psychometric testing and after 2-3 hours of vinpocetine taken, the psychometric testing done.The results of this study showed significant effects (p<0.05) of this drug on TRT, RRT and descending CFF but insignificant effect on (p>0.05) movement reaction time (MRT) and ascending CFF.These consequences indicate a positive effect of vinpocetine on central nervous system but not on the peripheral nervous system.

show abstract

Section: Discussionmentioning

confidence: 50%

The Effects of Vinpocetine on the Psychomotor Performances: Randomized clinical trial, single blind random clinical study

Al-Kuraishy¹,

Al-Windy²,

Al-Gareeb³

2012

JNUS

View full text Add to dashboard Cite

show abstract

“…Most studies performed in animal models used doses between 10 and 20 mg/kg [14,15]. These doses translated to humans would result in approximately 1,000 mg, which would be roughly a 20-fold increase in the current doses used in clinicaltrials [16][17][18].…”

Section: Discussionmentioning

confidence: 99%

Is There Treatment Effect of Vinpocetine on Autonomic Dysfunction in Rats With Alzheimer

Khan

Dolu²,

Gündüz³

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Alzheimer's disease (AD) shows less autonomic dysfunction. There was a lack of response or prolongation of its latency in skin sympathetic response. Vinpocetine is a classic inhibitor of PDE1 activity. Vinpocetine treatment has been shown to enhance performance on cognitive tests in humans. The efficacy of the use of vinpocetine in clinical trials has been controversial. A comparison of multiple studies evaluating vinpocetine use in AD was recently conducted. Our first aim was to assess dysautonomia in rat with AD electrophysiologically, using sympathetic skin response (SSR) test. The second aim of this study, evaluate the effect of vinpocetine treatment on Alzheimer autonomic dysfunction and attention deficiency.

show abstract

“…Винпоцетин ингибирует активность натриевых каналов в нервной ткани, что является основным механизмом фармакологических агентов с нейропротективными свойствами. Это свойство винпоцетина продемонстри-ровано в том числе в экспериментах эффективной бло-кады накопления натрия в нейронах, уменьшении зоны реперфузионного повреждения и нивелировании токси-ческого воздействия окислительного стресса в результа-те аноксии [12]. Показано, что винпоцетин защищает нейроны от токсичности глутамата и N-метил-d-аспартата (NMDA) [13], с чем также связаны его нейро-протективные свойства.…”

Section: стадияunclassified

Initial Forms of Cerebrovascular Insufficiency: Different Approaches to Therapy (On the Results of the Clinical and Epidemiological Program «profile»)

Коберская¹,

Tabeeva²,

Калимеева³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

Vinpocetine for cognitive impairment and dementia

Cited by 107 publications

References 19 publications

The Effects of Vinpocetine on the Psychomotor Performances: Randomized clinical trial, single blind random clinical study

The Effects of Vinpocetine on the Psychomotor Performances: Randomized clinical trial, single blind random clinical study

Is There Treatment Effect of Vinpocetine on Autonomic Dysfunction in Rats With Alzheimer

Initial Forms of Cerebrovascular Insufficiency: Different Approaches to Therapy (On the Results of the Clinical and Epidemiological Program «profile»)

Contact Info

Product

Resources

About